The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VOR | -53.43% | N/A | N/A | -99% |
| S&P | +13.22% | +85.17% | +13.11% | +76% |
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
No news articles found for Vor Biopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 99.8% |
| Market Cap | $333.30M | 593.4% |
| Market Cap / Employee | $2.10M | 0.0% |
| Employees | 159 | -5.4% |
| Net Income | -$812.68M | -2848.9% |
| EBITDA | -$28.11M | -1.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $160.46M | 203.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.81M | -90.2% |
| Short Term Debt | $0.25M | -93.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1676.47% | -1610.1% |
| Return On Invested Capital | -57.28% | 9.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$53.91M | -131.2% |
| Operating Free Cash Flow | -$53.66M | -130.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.43 | 1.36 | -0.14 | -0.20 | -130.86% |
| Price to Tangible Book Value | 20.89 | 18.52 | 61.23 | -0.20 | -102.08% |
| Enterprise Value to EBITDA | -0.58 | -1.86 | 0.00 | -5.63 | 764.53% |
| Return on Equity | -78.1% | -90.8% | -94.5% | -125.4% | 84.26% |
| Total Debt | $31.83M | $30.78M | $0.00M | $3.06M | -90.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
